BRPI0518571A2 - peptÍdeos de alfa timosina como adjuvantes de vacina contra cÂncer - Google Patents

peptÍdeos de alfa timosina como adjuvantes de vacina contra cÂncer

Info

Publication number
BRPI0518571A2
BRPI0518571A2 BRPI0518571-8A BRPI0518571A BRPI0518571A2 BR PI0518571 A2 BRPI0518571 A2 BR PI0518571A2 BR PI0518571 A BRPI0518571 A BR PI0518571A BR PI0518571 A2 BRPI0518571 A2 BR PI0518571A2
Authority
BR
Brazil
Prior art keywords
alpha
cancer vaccine
peptides
thymosine
subject
Prior art date
Application number
BRPI0518571-8A
Other languages
English (en)
Inventor
Gustavo Antonio Moviglia
Alfred R Rudolph
Original Assignee
Sciclone Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals Inc filed Critical Sciclone Pharmaceuticals Inc
Publication of BRPI0518571A2 publication Critical patent/BRPI0518571A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49—Breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

PEPTÍDEOS DE ALFA TIMOSINA COMO ADJUVANTES DE VACINA CONTRA CÂNCER. Uma combinação farmacêutica e método para melhorar a eficácia de vacina contra câncer em um sujeito, utilizar uma vacina contra câncer que provoca resposta imune capaz de eliciar uma resposta de sistema imune em um sujeito, e uma vacina de aumento de quantidade eficaz de um peptídeo alfa timosina, que melhora a resposta de sistema imune no sujeito, em que a vacina contra câncer e o peptídeo alfa timosina podem ser administrados separadamente ou em conjunto.
BRPI0518571-8A 2004-12-06 2005-12-06 peptÍdeos de alfa timosina como adjuvantes de vacina contra cÂncer BRPI0518571A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63317504P 2004-12-06 2004-12-06
PCT/US2005/043985 WO2006062917A2 (en) 2004-12-06 2005-12-06 Alpha thymosin peptides as cancer vaccine adjuvants

Publications (1)

Publication Number Publication Date
BRPI0518571A2 true BRPI0518571A2 (pt) 2008-11-25

Family

ID=36578462

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518571-8A BRPI0518571A2 (pt) 2004-12-06 2005-12-06 peptÍdeos de alfa timosina como adjuvantes de vacina contra cÂncer

Country Status (15)

Country Link
US (1) US20100092499A1 (pt)
EP (1) EP1835931A4 (pt)
JP (1) JP2008523067A (pt)
KR (1) KR20070086663A (pt)
CN (1) CN101072582B (pt)
AU (1) AU2005314271B2 (pt)
BR (1) BRPI0518571A2 (pt)
CA (1) CA2588685A1 (pt)
EA (1) EA015510B1 (pt)
IL (1) IL183264A (pt)
MX (1) MX2007006717A (pt)
NO (1) NO20072705L (pt)
NZ (1) NZ555571A (pt)
UA (1) UA90493C2 (pt)
WO (1) WO2006062917A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2708168A1 (en) * 2007-12-14 2009-06-25 Sciclone Pharmaceuticals, Inc. Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (hsaa)
EP2427213B1 (en) * 2009-05-08 2015-04-01 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
CN103458681A (zh) * 2011-02-09 2013-12-18 赛生制药有限公司 用于预防感染、降低感染的严重性、及治疗感染的胸腺素α肽
EP2804626B1 (en) * 2012-01-20 2019-05-01 Fernando Thome Kreutz Autologous cancer cell vaccine
US20150031617A1 (en) * 2012-03-08 2015-01-29 Sciclone Pharmaceuticals, Inc. Use of thymosin alpha for treatment of purulent rhinosinusitis
TWI683667B (zh) * 2014-10-21 2020-02-01 開曼群島商賽生製藥國際有限公司 用免疫刺激物治療癌症
CN107281476B (zh) * 2017-04-06 2020-11-24 中国医科大学 一种抗原肽RL-佐剂CpGODN7909偶联物及其制备方法和应用
RU2645957C1 (ru) * 2017-04-10 2018-02-28 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения лучевых повреждений мочевого пузыря
RU2663468C1 (ru) * 2017-09-25 2018-08-06 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения местно-распространенного нерезектабельного рака поджелудочной железы

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US653758A (en) * 1900-03-20 1900-07-17 Austin Gale Hay-stacking device.
DE2604845A1 (de) 1976-02-07 1977-08-18 Knoll Ag Neue piperazinderivate
JPH0420624A (ja) * 1990-02-06 1992-01-24 Kanji Yokoe 勾配側溝施工法及び当該工法に使用する可変側溝
US6537585B1 (en) * 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
PL354093A1 (en) * 1999-06-30 2003-12-29 Corixa Corporationcorixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
CA2498591A1 (en) * 2001-10-26 2003-05-01 Immuno-Rx, Inc. Immunotherapy for reversing immune suppression
BR0213554A (pt) * 2001-10-26 2004-10-26 Rhode Island Hospital Timosina para aumento da imunização genética
MXPA05000078A (es) * 2002-06-28 2005-04-11 Sciclone Pharmaceuticals Inc Metodo para sobre-regular la expresion de antigeno tumoral utilizando timalfasina, y composiciones y usos.
BRPI0408892A (pt) * 2003-03-28 2006-04-11 Sciclone Pharmaceuticals Inc uso de timosina alfa 1 para tratar as infecções por arpergillus
EP2633866A3 (en) * 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
EP2427213B1 (en) * 2009-05-08 2015-04-01 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers

Also Published As

Publication number Publication date
CN101072582B (zh) 2012-06-27
CN101072582A (zh) 2007-11-14
IL183264A (en) 2010-12-30
JP2008523067A (ja) 2008-07-03
IL183264A0 (en) 2007-09-20
UA90493C2 (ru) 2010-05-11
EP1835931A4 (en) 2008-12-17
WO2006062917A2 (en) 2006-06-15
US20100092499A1 (en) 2010-04-15
EA015510B1 (ru) 2011-08-30
AU2005314271A1 (en) 2006-06-15
NZ555571A (en) 2009-02-28
CA2588685A1 (en) 2006-06-15
AU2005314271B2 (en) 2011-06-16
NO20072705L (no) 2007-09-05
EP1835931A2 (en) 2007-09-26
KR20070086663A (ko) 2007-08-27
MX2007006717A (es) 2007-08-06
WO2006062917A3 (en) 2006-11-16
EA200701166A1 (ru) 2008-02-28

Similar Documents

Publication Publication Date Title
BRPI0518571A2 (pt) peptÍdeos de alfa timosina como adjuvantes de vacina contra cÂncer
WO2012027379A3 (en) Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
ES2512141T3 (es) Análogo peptídico de oxintomodulina
BRPI0905725B8 (pt) vacina e embalagem farmacêutica
MX2009001412A (es) Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas.
AR054251A1 (es) Vacuna de toxoide de c. perfringens alfa
BR112016024352A2 (pt) ?cepa de listeria recombinante, listeria recombinante, composição farmacêutica, e, métodos de induzir uma resposta imune contra um tumor ou um câncer em um indivíduo humano e de listeria?
BRPI0518793A2 (pt) mÉtodos para tratar, controlar ou prevenir uma doenÇa ou distérbio de imunodeficiÊncia, e para melhorar a resposta imune a um imunogene, e, composiÇço farmacÊutica
WO2007103048A3 (en) Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
BRPI0906997A2 (pt) Proteína, uso da proteína combinante ou fragmento da mesma, método para induzir uma resposta imune em um individuo, método para tratar um paceinte, construção de ácido nicleico, vetor de ezpressão o ucélula hospedeira, vacina, anticorpo, e, composição farmaceutica
BR112014021102A2 (pt) Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
EA201170493A1 (ru) Микроорганизмы и вакцины, зависимые от репликации неприродных аминокислот
BRPI0510430A (pt) composições e métodos para vacinação mucosal
WO2007079190A3 (en) Device and method for enhancing immune response by electrical stimulation
WO2007120673A3 (en) Immunogenic wt-1 peptides and methods of use thereof
BR112015009541A2 (pt) novos adjuvantes de mucosa e sistemas de aplicação
ATE532469T1 (de) In eine menschliche oder tierische knochenstruktur einführbares konnektionsmittel und zugehöriges lokalisationssystem
DK1576967T3 (da) Rekombinant protein, der bærer epitoper fra det humane papillomvirus indsat i et adenylatcyclaseprotein eller et fragment deraf samt dets terapeutiske anvendelse
CL2009001195A1 (es) Adyuvante inmune que comprende un inhibidor de iap capaz de modular la actividad inmune; composicion farmaceutica y vacuna que lo comprenden; metodo para mejorar una respuesta inmune de un individuo; metodo para tratar un cancer en un individuo; metodo para tratar infeccion; metodo para tratar trastornos autoinmune.
ATE521629T1 (de) Matrixmetalloproteinase-11-impfstoff
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden
BR112014023572A2 (pt) método para tratar ou prevenir dano de articulação em um indivíduo com ra precoce ou ra incipiente, uso de um agente ou combinação de agentes que estimulam uma resposta tolerogênica específica de antígeno a um polipeptídeo de agrecan, e agente ou combinação de agentes
ES2530670T3 (es) Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo
GB2453491A (en) Immunogenic proteins of burkholderia pseudomallei and uses thereof
WO2011053789A3 (en) Pharmaceutical composition and methods to enhance cytotoxic t-cell recognition and maintain t-cell memory against a pathogenic disease

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: BASEADO NO ARTIGO 216 1O DA LPI, PARA QUE A PETICAO NO 20080118249/RJ DE 09/09/2008 SEJA ACEITA, APRESENTE COPIA AUTENTICADA DA PROCURACAO.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 8A, 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.